| Globe & Mail (Toronto, Canada) 1999 Leonard Zehr |
| Title | Subject | Authors |
|---|
| Allelix to merge with NPS Pharmaceuticals. | News, opinion and commentary | Leonard Zehr |
| AltaRex says ovarian cancer drug results positive. | News, opinion and commentary | Leonard Zehr |
| Analysts see bright future for QLT. | News, opinion and commentary | Leonard Zehr |
| Axcan expected to match LHC bid for Scandipharm. | News, opinion and commentary | Leonard Zehr |
| Axcan Pharma to buy rest of U.S. marketing partner. | News, opinion and commentary | Leonard Zehr |
| BioChem chief executive gets $1.7-million in record year. | News, opinion and commentary | Leonard Zehr |
| Biovail snags U.S. firm in cash and stock deal. | News, opinion and commentary | Leonard Zehr |
| Canadian Medical Labs loses zeal for Med-Chem takeover. | News, opinion and commentary | Leonard Zehr |
| Canadian Medical results shatter estimates. | News, opinion and commentary | Leonard Zehr |
| Cangene withdraws offer for Hyal. | News, opinion and commentary | Leonard Zehr |
| Court likely to name Med-Chem receiver. | News, opinion and commentary | Leonard Zehr |
| Dimethaid, J&J sign deal for arthritis lotion distribution in the US. | News, opinion and commentary | Leonard Zehr |
| Dimethaid stock rises 8% on expectations for arthritis lotion. | News, opinion and commentary | Leonard Zehr |
| Drug firms facing short-term financial pressures, study says. | News, opinion and commentary | Leonard Zehr |
| Generics lash out at health regulations. | News, opinion and commentary | Leonard Zehr |
| GlycoDesign acquires Vascular Therapeutics. | News, opinion and commentary | Leonard Zehr |
| Group denied Oralife injunction. | News, opinion and commentary | Leonard Zehr |
| Haemacure halts trials for biological glue. | News, opinion and commentary | Leonard Zehr |
| Hyal board accepts Cangene takeover offer. | News, opinion and commentary | Leonard Zehr |
| Hyal reports loss decreased by 24%. | News, opinion and commentary | Leonard Zehr |
| IcePro shoots to score as one-stop rink supplier. | News, opinion and commentary | Leonard Zehr |
| Lorus therapeutics to acquire Genesense. | News, opinion and commentary | Leonard Zehr |
| MDS profit climbs 23%. | News, opinion and commentary | Leonard Zehr |
| Novopharm takes writedown on drug development delay. | News, opinion and commentary | Leonard Zehr |
| Oralife misrepresented his research: Dentist. | News, opinion and commentary | Leonard Zehr |
| Patheon sees faster revenue growth. | News, opinion and commentary | Leonard Zehr |
| QLT puts 2.6 million new shares up for sale. | News, opinion and commentary | Leonard Zehr |
| QLT seeks approval for vision drug in EU. | News, opinion and commentary | Leonard Zehr |
| QLT shares rise on drug price tag. | News, opinion and commentary | Leonard Zehr |
| Receiver appointed for insolvent Hyal. | News, opinion and commentary | Leonard Zehr |
| Skye Pharma to sell 20% interest to U.S. firm. | News, opinion and commentary | Leonard Zehr |
| Surging Biovail merely catching up. | News, opinion and commentary | Leonard Zehr |
| Synsorb braces for key FDA meeting. | News, opinion and commentary | Leonard Zehr |
| Synsorb won' test E. coli-related drug. | News, opinion and commentary | Leonard Zehr |
| Timing of issue, earnings drives down laser center. | News, opinion and commentary | Leonard Zehr |
| TLC goes for a ride as it denies raft of reports. | News, opinion and commentary | Leonard Zehr |
| TLC the laser center looks south. | News, opinion and commentary | Leonard Zehr |
| TLC The Laser Center to pierce U.S. market with new venture. | News, opinion and commentary | Leonard Zehr |
| U.K. drug firm rescues troubled Hyal. | News, opinion and commentary | Leonard Zehr |
| U.K. firm to use court in bid for Hyal assets. | News, opinion and commentary | Leonard Zehr |
| U.S. deal boosts TLC stock 20%. | News, opinion and commentary | Leonard Zehr |
| U.S., U.K. okay Hemosol blood substitute tests. | News, opinion and commentary | Leonard Zehr |
| Xillix admits survival in jeopardy. | News, opinion and commentary | Leonard Zehr |
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
